scholarly journals In vitro non-viral gene delivery with nanofibrous scaffolds

2005 ◽  
Vol 33 (19) ◽  
pp. e170-e170 ◽  
Author(s):  
D. Liang
Keyword(s):  
Gene Delivery ◽  
Viral Gene ◽  
Nanofibrous Scaffolds ◽  
Viral Gene Delivery

How to screen non-viral gene delivery systems in vitro?

2011 ◽  
Vol 154 (3) ◽  
pp. 218-232 ◽  
Author(s):  
Ethlinn V.B. van Gaal ◽  
Roel van Eijk ◽  
Ronald S. Oosting ◽  
Robbert Jan Kok ◽  
Wim E. Hennink ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Delivery Systems ◽  
Viral Gene ◽  
Viral Gene Delivery

scholarly journals SUN-140 TMEPAI Inhibits SMAD 2/3 Mediated Muscle Wasting

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Swati Kharoud ◽  
Kelly Louise Walton ◽  
Adam Hagg ◽  
Georgia Goodchild ◽  
Justin Chen ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Gene Delivery ◽  
Muscle Mass ◽  
Muscle Wasting ◽  
Activin A ◽  
Viral Gene ◽  
Soluble Receptors ◽  
Skeletal Muscle Wasting ◽  
Viral Gene Delivery

Abstract Inhibition of myostatin and activin activity using ligand traps, such as soluble receptors, follistatin and propeptides, can markedly increase skeletal muscle mass in healthy mice and ameliorate wasting in models of cancer cachexia and muscular dystrophy. Though effective, clinical translation of these approaches has been hindered by off-target effects. Toward the goal of developing tissue-specific myostatin/activin interventions, we explored the ability of transmembrane prostate androgen-induced (TMEPAI) to promote growth of skeletal muscle. TMEPAI, a transcriptional target of activin in muscle, is a known inhibitor of TGF-β1-mediated SMAD 2/3 signalling. In this study we show that TMEPAI also blocks activin A, activin B, myostatin and GDF-11 in vitro activity. Adeno-associated viral (AAV) gene delivery of TMEPAI into healthy mice increased local muscle mass by as much as 30%. Increased muscle mass was attributed to hypertrophy of fibres in TMEPAI-expressing muscles, and was coincident with an upregulation in markers of protein synthesis (pAkt, pMTOR, p70S6K). The ability of TMEPAI to block activation of the canonical activin/myostatin-SMAD 2/3 axis, was demonstrated by co-injecting AAV6:activin A and AAV6:TMEPAI into healthy mice. In this setting, TMEPAI blocked activin-induced phosphorylation of SMAD3 and associated skeletal muscle wasting. Finally, delivery of AAV6:TMEPAI into tibialis anterior muscles of mice bearing C26 tumours prevented muscle atrophy normally associated with this model. The results support that viral gene delivery of TMEPAI can effectively increase muscle mass via inactivation of the activin/myostatin-SMAD 2/3 pathway.

scholarly journals Non-Viral in Vitro Gene Delivery: It is Now Time to Set the Bar!

Pharmaceutics ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 183 ◽  
Author(s):  
Nina Bono ◽  
Federica Ponti ◽  
Diego Mantovani ◽  
Gabriele Candiani
Keyword(s):  
Gene Delivery ◽  
Viral Gene ◽  
Limited Information ◽  
Internal Reference ◽  
Experimental Conditions ◽  
Testing Conditions ◽  
Delivery Vector ◽  
Gene Delivery Vectors ◽  
Viral Gene Delivery

Transfection by means of non-viral gene delivery vectors is the cornerstone of modern gene delivery. Despite the resources poured into the development of ever more effective transfectants, improvement is still slow and limited. Of note, the performance of any gene delivery vector in vitro is strictly dependent on several experimental conditions specific to each laboratory. The lack of standard tests has thus largely contributed to the flood of inconsistent data underpinning the reproducibility crisis. A way researchers seek to address this issue is by gauging the effectiveness of newly synthesized gene delivery vectors with respect to benchmarks of seemingly well-known behavior. However, the performance of such reference molecules is also affected by the testing conditions. This survey points to non-standardized transfection settings and limited information on variables deemed relevant in this context as the major cause of such misalignments. This review provides a catalog of conditions optimized for the gold standard and internal reference, 25 kDa polyethyleneimine, that can be profitably replicated across studies for the sake of comparison. Overall, we wish to pave the way for the implementation of standardized protocols in order to make the evaluation of the effectiveness of transfectants as unbiased as possible.

scholarly journals Non-viral gene delivery of human apoA1 into mammalian cells in vitro and in vivo

2004 ◽  
Vol 20 (1-2) ◽  
pp. 25-32 ◽  
Author(s):  
O. K. Toporova ◽  
S. N. Novikova ◽  
L. I. Lihacheva ◽  
O. M. Suhorada ◽  
T. A. Ruban ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Mammalian Cells ◽  
Viral Gene ◽  
Viral Gene Delivery

Synergistic effects between natural histone mixtures and polyethylenimine in non-viral gene delivery in vitro

2010 ◽  
Vol 400 (1-2) ◽  
pp. 86-95 ◽  
Author(s):  
Anne Schneeweiss ◽  
Kevin Buyens ◽  
Matthias Giese ◽  
Niek Sanders ◽  
Sebastian Ulbert
Keyword(s):  
Gene Delivery ◽  
Synergistic Effects ◽  
Viral Gene ◽  
Viral Gene Delivery
Sign in / Sign up

Export Citation Format

Share Document